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Objectives. To determine the relationship between Vascular Endothelial (VE)-cadherin expression in carotid plaques,
carotid plaque morphology and clinical findings of carotid disease.
Materials and methods. Fifty-three formalin-fixed, paraffin embedded specimens of human carotid atherosclerotic plaque
obtained by endarterectomy and 20 normal postmortem arteries (control group) were studied. Thirty patients were
symptomatic and 23 asymptomatic. The expression of VE-cadherin was examined by an avidin–biotin immunoperoxidase
technique using specific monoclonal antibodies against this molecule. We used a scale for the estimation of the expression of
the VE-cadherin, in which negative expression was indicated by 0, weak expression by 1, and strong expression by 2. In serial
sections we also determined the cellular phenotype of atherosclerotic plaques: i.e. the endothelial cells (F8), macrophage
(CD68) and smooth muscle cells. Possible relations between variables in statistical analysis were examined by the chi-square
test or Fisher’s exact test.
Results. Expression of VE-cadherin was observed in small newly established vessels, particularly in areas with intense
inflammatory infiltrations by macrophages and leucocytes. A strong expression of VE-cadherin was evident particularly in
symptomatic instead in asymptomatic patients (43% vs. 13%, p ¼ 0:057), in high degree stenosis group (81% vs. 0%,
p ¼ 0:005), and in patients with ischaemic infarct in brain scan (71% vs. 23%, p ¼ 0:021). On the other hand, there was no
relation between molecule expression and plaque ultrasonic characteristics (echogenic or echolucent, p ¼ 0:499).
Finally, there was a significant statistical correlation in the expression of VE-cadherin and the histological type of the plaque,
namely fibrotic and complicated plaques. Strong VE-cadherin expression was observed in 64% of complicated plaques
instead of 6.5% in fibrotic plaques ðp ¼ 0:001Þ:
Conclusion. An intense expression of VE-cadherin in carotid plaques is linked with plaque instability, high degree of
stenosis and clinical events. This molecule seems to be a marker of progression of the atherosclerotic plaque.
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Introduction
Although there are several risk factors for ischemic
stroke,1 it appears that the morphology of the
atherosclerotic plaque at the carotid bifurcation plays
a crucial role. Clinical and experimental data suggest
that plaques with rupture or ulceration and intrapla-
que hemorrhage, the so-called ‘unstable’ plaques, are
at high risk of producing thromboembolic events in
cerebral circulation.2 – 4
Recent studies have focused on the role of immune
mediators and inflammation in the destabilization of
atherosclerotic plaque.5 – 8 It has been suggested that
the recruitment of these cells occurred via neovascu-
lature (angiogenesis), formed within the intima of
complex plaques.6,9 Although molecular mechanisms
involved in this process remain poorly understood,
cell adhesion molecules seem to be a key factor.9,10
Vascular endothelial cadherin (VE-cadherin), is a
Ca2þ-dependent, endothelium-specific, cell adhesion
molecule. It is the major component of adherens
junctions in the endothelium and interacts, via its
cytoplasmic tail, with three proteins of the armadillo
family, called a-catenin, b-catenin, and g-catenin
(plakoglobin). VE-cadherin/catenin complex is essen-
tial for remodeling into a network of newly formed
vessels.11 – 13 VE-cadherin therefore is presumed to
Eur J Vasc Endovasc Surg 26, 523–528 (2003)
doi: 10.1016/S1078-5884(03)00342-3, available online at http://www.sciencedirect.com on
Presented at the XVI annual meeting of the ESVS.
*Corresponding author. Elias A. Bastounis, 4 Antinoros Street,
Athens 116 34, Greece.
1078–5884/050523 + 06 $35.00/0 q 2003 Elsevier Ltd. All rights reserved.
contribute essentially to neovascularization. However,
there are no previous reported studies which have
examined the relationship of the expression of this
molecule with clinical and histopathological data.
The present study was undertaken to investigate
VE-cadherin expression in carotid atherosclerotic
plaques, its relationship with plaque instability and
whether this molecule might be a marker for sympto-
matic carotid lesions.
Materials and Methods
Patients
Fifty-three carotid plaques were collected from 50
consecutive patients (43 men and 7 women, mean age
69 years) who had internal carotid artery stenosis
.70% and were subjected to carotid endarterectomy.
The operation was performed by the same technique
in all cases, with shunt insertion and closure of the
arteriotomy with venous patch. Risk factors (smoking,
hypertension, diabetes and hyperlipidemia) and vas-
cular comorbidities (ischemic heart disease, aneur-
ysms, peripheral arterial occlusive disease) were
recorded (Table 1).
All patients were evaluated preoperatively by a
neurologist and were assigned as symptomatic and
asymptomatic. They also underwent a cerebral CT
scan for possible identification of brain infarcts.
Color Doppler ultrasonography was used to define
the echogenicity of lesions. Predominantly echolucent
plaques were classified as hypoechoic, while predo-
minantly echogenic plaques as hyperechoic.14
Arteriography of the carotid bifurcation was per-
formed in all patients and the degree of stenosis was
determined according NASCET criteria.15 Based on
these measurements, stenotic lesions were divided
into three subgroups(70–79%, 80–89%, 90–99%).
Tissue specimens
Carotid plaque specimens were removed completely
intact in the operating room and fixed immediately in
10% buffered paraformaldehyde solution, for conven-
tional histology and immunohistochemistry.
After embedding each specimen in paraffin, it was
stained with haematoxylin and eosin; a pathologist
examined blindly each specimen to assess atheroma-
tous plaque morphology, using the American Heart
Association classification of atherosclerotic plaques.16
According to this classification, carotid plaques were
assigned as fibroatherotic (type V) and complicated
(type VI). The latter type included plaques with
intraplaque hemorrhage, ulcer or thrombus, which
were considered unstable.
Twenty healthy carotid arteries obtained in
autopsies, served as tissue samples for the ‘baseline-
expression’ of the examined factors on human arteries.
Immunohistochemical analysis
Immunohistochemical analysis was performed by two
examiners, blinded to the clinical and histological
data. The following antibodies were used: VE-cad-
herin goat polyclonal antibody, CD34 mouse mono-
clonal, CD68 mouse monoclonal, SMS actin mouse
monoclonal, and catenin- a,b,g mouse monoclonal
(Table 2).
Immunohistochemistry was performed according
to the indirect streptavidin – biotin-peroxidase
method; 5 mm paraffin sections were maintained on
poly-L-lysine-coated slides, dewaxed, rehydrated and
incubated for 30 min with 0.3% hydrogen peroxide to
quench the endogenous peroxidase activity. Unmask-
ing of the related proteins was carried out (see Table 2).
Sections were incubated with the appropriate primary
antibody in a dilution as shown in Table 2. Biotin-
conjugated secondary antibody was added at a 1:200
dilution for 1 h at room temperature. The next stage
comprised 30 min incubation in Strept AB Complex
(1:100 stock biotin solution, 1:100 stock streptavidin-
peroxidase solution) (DAKO). For color development
we used 3,30-diaminobenzidine tetrahydrochloride
(DAB, Sigma) and haematoxylin as counterstain.
Images were taken using a Zeiss Axiolab micro-
scope (Carl Zeiss GmbH, Jena, Germany) with a
mechanical stage, fitted to a Sony-iris CCD videoca-
mera (Sony Corp., Tokyo, Japan). The videocamera
was connected to a Pentium III personal computer
loaded with the appropriate image analysis software.
Slides were examined at high power magnification
( £ 400). A first elaboration of digital images was done
Table 1. Patients’ demographics and risk factors.
Mean age (range) 69.08 years (55–80)
Male/female 43/7
Smoking 43 (86%)
Current/past smokers 17/26
Hypertension 42 (84%)
Diabetes 16 (32%)
Hyperlipidemia 25 (50%)
Ischemic heart disease 27 (54%)
Aneurysm 6 (12%)
Peripheral arterial occlusive disease 15 (30%)
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by using the image scan pro software (Science GmbH,
Erkrath, Germany). Further evaluation was made via
the Color Estimation v.2.0., a specific application
developed in the Department of Pathology of Athens
University in a Microsoft Visual Basic 5.0 (Microsoft
Corp., Redmond, WA) environment, for the evaluation
of immunohistochemical color images. The stained
cells were selected manually, but the measurement of
staining intensity was performed according to the
mean value of density, which was calculated
automatically.
VE-cadherin expression in carotid atherosclerotic
lesions was measured on a semiquantitative scale
ranging from 0 to 2, in which 0 indicated absence of
any expression; 1 weak expression; and 2 strong
expression. For statistical purposes, when necessary,
these categories suppressed to weak (0 and 1) and
strong (2).
Statistical analysis
Differences in VE-cadherin expression among sub-
groups of patients was tested by the Pearson chi-
squared test if the expected values for any cell were
,5; otherwise, the Fisher’s exact test (two-sided) was
used. Statistical analysis was performed with the SPSS
10.0 statistical program, and values of P , 0:05 were
considered significant.
Results
Of the cohort of 53 carotid lesions, 30 were sympto-
matic and 23 asymptomatic; however only seven cases
were associated with an infarct in the ipsilateral
hemisphere and the remaining had negative findings
in the brain CT scan. Seventeen lesions produced
stenosis less than 80%, 17 had 80–89% stenosis, and 19
had over than 90% stenosis. There was no difference in
degree of stenosis between symptomatic and asymp-
tomatic patients. Color duplex ultrasound scan ident-
ified 13 echolucent plaques and 40 echogenic. All
atherosclerotic carotid lesions were available for
histologic assessment: 31 were fibroatheromas (AHA
class V) and 22 were complicated atherosclerotic
plaques (hemorrhage, ulceration, necrotic core)
(AHA class VI).
In normal human arteries VE-cadherin was con-
sistently expressed in the endothelial cells and the
vasa vasorum with selective localization at the inter-
cellular junctions. This expression was not observed in
the intima and the inner two thirds of the media.
In atherosclerotic arterial segments, VE-cadherinTa
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expression was present not only in the adventitia and
media, but also in the intima, where it was restricted to
the endothelial cells in areas of neovascularization
(Fig. 1). This process was developed mainly beneath
the necrotic core between the intima and media. In
complicated plaques an intense expression of CD68
and CD3 antibodies (macrophages and leucocytes)
was observed, while in fibrotic plaques there was no or
weak expression. In areas of neovascularization of
atherosclerotic segments, there was a moderate or high
expression of b-catenin (Fig. 2) and low or moderate
expression of a-catenin, but low or no expression of g-
catenin.
The presence of VE-cadherin was detected in small
newly established vessels, particularly in areas with
intense inflammatory infiltrations by macrophages
and leucocytes (Fig. 3). Moreover, an intense
expression of VE-cadherin was constantly associated
with an increased concentration of those cells.
The distribution of VE-cadherin expression among
subgroups of cases are demonstrated in Table 3. An
intense expression of VE-cadherin was evident par-
ticularly in symptomatic instead of asymptomatic
patients (43% vs. 13%, p ¼ 0:057), in high degree
(.90%) stenotic lesions (81% vs. 0%, p , 0:0005) and
in cases with ischaemic infarct in brain scan (71% vs.
23%, p ¼ 0:021). On the other hand, there was no
relation between molecule expression and plaque
echogenicity ðp ¼ 0:499Þ:
There was also a very significant statistical differ-
ence in the expression of VE cadherin between fibrotic
and complicated plaques. Strong VE-cadherin
expression was observed in 64% of complicated
plaques instead of 6.5% in fibrotic plaques ðp ,
0:0005Þ:
Discussion
At present, the only confirmed criterion to identify
carotid lesions at high risk of producing stroke is the
degree of stenosis.15,17,18 Discrepancies in outcome of
equally severe symptomatic and asymptomatic
lesions, however, suggest that plaque features and
vascular biology might also play an important role.
Development of intraplaque hemorrhage, plaque
rupture or ulceration, morphological characteristics
of the unstable plaque, are associated with a high
likelihood of cerebral ischemic events.19 Infiltration of
Fig. 1. Expression of VE-cadherin (arrows) in area of
neovascularization (V).
Fig. 3. Expression of VE-cadherin (arrows) in newly formed
vessels (V).
Fig. 2. Expression of beta-catenin (arrows) in a vessel (V).
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inflammatory cells to the surface of carotid plaques via
neovascularization and cell adhesion molecules may
trigger plaque instability.6 – 9
The implication of intimal neovasculature as a key
component in plaque activation has been documen-
ted.6,7 However, little attention has been focused on
VE-cadherin in carotid atherosclerotic plaque,
although it is considered a very significant molecule
in angiogenesis. VE-cadherin/catenin complex is
implicated in the organization and maturation of
neovessels and in the protection of endothelial
integrity.20,21
Our observation that VE-cadherin is deposited
exclusively in neovessels surrounded by inflammatory
cells supports previous evidence reported by Bobry-
shev et al. that in this process VE-cadherin plays a
central role.10 Our study expands the knowledge
regarding its role and demonstrates the increasing
intensity of VE-cadherin expression observed in
plaques with high likelihood of producing symptoms.
A high expression of VE-cadherin was observed in
complicated plaques, along with an analogous
expression of beta-catenin, a moderate expression of
alpha-catenin and no or low expression of placoglobin.
It has been reported that placoglobin is necessary for
the formation of ‘mature’ junctions;20 it appears,
therefore, that the loss of placoglobin in neovessels
renders junctions to function improperly, increasing
vascular permeability.
The present study has established a significant
higher expression of VE-cadherin in complicated
plaques as well as a higher expression in high-grade
stenotic lesions. This observation could suggest that
VE-cadherin is also important for the progression of
carotid lesions. In addition, the strong expression of
this molecule in patients with cerebral infarct and
clinical symptoms reflects an association between
neovascularization and symptomatic carotid disease,
as has been demonstrated in previous reports.6,7 VE-
cadherin therefore, could be considered as a marker of
advanced carotid atherosclerotic plaques.
Although mechanisms underlying plaque acti-
vation has not been clearly elucidated, data from the
present work and other investigations suggest that
macrophages and smooth muscle cells release angio-
genic factors,22 which they cause migration and
proliferation of endothelial cells in the intima and
expression of VE-cadherin.13 This molecule is
involved in maturation, expansion, branching and
remodeling of endothelial cells into a network of
newly blood vessels in the plaque.13 Neovasculariza-
tion is the main route for the migration of inflamma-
tory cells into the intima with participation of cell
adhesion molecules (E-selectin, intercellular adhesionTa
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molecule-1 and vascular cell adhesion molecule-1).9,23
Plaque instability is thought to be due to breakdown
on the extracellular matrix caused by enzymes
secreted by the macrophage cells.24
In conclusion, VE-cadherin is a molecule of utmost
importance for plaque neovascularization and a
subsequent development of plaque instability. Strong
expression of this molecule indicates an advanced
carotid atherosclerotic disease. However, further
insight in molecular mechanisms of intimal angiogen-
esis is required and future studies are necessary to
investigate the potential utility of VE-cadherin in
antiatherogenic strategies.
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